Antibody-Mediated Drug Delivery Systems: General Review and Applications

Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications

Volumn , Issue , 2012, Pages 1-12

  Kaur, Navdeep ^a   Subramani, Karthikeyan ^b   Pathak, Yashwant ^c  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Antibody engineering, innovations in therapeutic efficacy; Antibody mediation; Antibody therapeutics and novel models of action; Antibody mediated drug delivery systems, and applications

Indexed keywords

EID: 84886130288     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118229019.ch1     Document Type: Chapter

References (50)

1. http://en.wikipedia.org/wiki/Antibody.
2. Li, J., Zhu, Z. (2010). Research and development of next generation of antibody-based therapeutics. Acta Pharmacol. Sin. 31(9); 198-207.
3. http://www.bloomberg.com/news/2010-11-25/novartis-teva-may-get-billion-d ollar-boost-from-neweu- rules.html.
4. http://www.brighthub.com/science/medical/articles/13068.aspx.
5. http://www.webmd.com/a-to-z-guides/immunoglobulins.
6. http://www.ehow.com/facts_5489655_types-antibodies.html.
7. http://en.wikipedia.org/wiki/IgE.
8. Steinitz, M. (2009). Three decades of human monoclonal antibodies: past, present and future developments. Hum. Antibodies. 18(1-2); 1-10.
9. Parker, D. C. (1993). T cell-dependent B cell activation. Annu. Rev. Immunol. 11, 331-360.
10. http://www.microrao.com/micronotes/pg/humoral_immunity.pdf.
11. http://en.wikipedia.org/wiki/B_cell.
12. http://en.wikipedia.org/wiki/Antibody.
13. Goldenberg, D. M. (2007). Radiolabelled monoclonal antibodies in the treatment of metastatic cancer. Curr. Oncol. 14(1); 39-42.
14. http://www.immunomedics.com/5clinical/clinical_pipeline.html.
15. Nielsen, U. B., Kirpotin, D. B., Pickering, E. M., Hong, K., Park, J. W., Refaat Shalaby, M., Shao, Y., et al. (2002). Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta Mol. Cell Res., 1591(1-3); 109-118.
16. Heitner, T., Moor, A., Garrison, J. L., Marks, C., Hasan, T., Marks, J. D. (2001). Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J. Immunol. Methods, 248(1-2); 17-30.
17. He J., Wang Y., Feng J., Zhu X., Lan X., Iyer A.K., Zhang N., Seo Y., VanBrocklin H. F., Liu B. (2010). Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J. Nucl. Med. 51(3); 427-432. Epub Feb. 11, 2010.
18. Turturro, F. (2007). Denileukindiftitox: a biotherapeutic paradigm shift in the treatment of lymphoidderived disorders. Expert Rev. Anticancer Ther. 7, 11-17.
19. Gattenl̈ohner, S., J̈orissen, H., Huhn, M., Vincent, A., Beeson, D., Tzartos, S., Mamalaki, A., Etschmann, B., Muller-Hermelink, H. K., Koscielniak, E., Barth, S., Marx, A. (2010). A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J. Biomed. Biotechnol. 2010:187621. Epub Feb. 24, 2010.
20. Ducry, L., Stump, B. (2010). Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem., 21(1); 5-13.
21. Alley, S. C., Okeley, N. M., Senter, P. D. (2010). Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14(4); 529-537.
22. http://www.immunogen.com/wt/page/other.
23. http://www.immunomedics.com/5clinical/clinical_overview.html.
24. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_vi ew_&confID=73&abstractID= 30405.
25. http://www.seagen.com/product_pipeline_sgn75.shtml.
26. http://www.seagen.com/product_pipeline_sgn35.shtml.
27. http://www.seagen.com/product_pipeline_asg5me.shtml.
28. http://www.seagen.com/product_pipeline_dacetuzumab.shtml.
29. http://www.seagen.com/product_pipeline_sgn70.shtml.
30. http://www.seagen.com/product_pipeline_preclinical_programs.shtml.
31. http://www.immunogen.com/wt/page/im388.
32. http://www.immunogen.com/wt/page/sar3419.
33. http://www.immunogen.com/wt/page/IMGN901b.
34. http://www.immunogen.com/wt/page/trastuzumab_DM1.
35. http://www.celldextherapeutics.com/wt/page/cancer.
36. http://www.gene.com/gene/pipeline/status/oncology/anti-cd22/.
37. http://www.viventia.com/products.html.
38. Robinson, M. K., Shaller, C., Garmestani, K., Plascjak, P. S., Hodge, K. M., Yuan, Q. A., Marks, J. D., Waldmann, T. A., Brechbiel, M. W., Adams, G. P. (2008). Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alphaemitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin. Cancer Res., 14(3); 875-882.
39. Shimazaki, K., Lepin, E. J., Wei, B., Nagy, A. K., Coulam, C. P., Mareninov, S., Fu, M., Wu, A. M., Marks, J. D., Braun, J., Gordon, L. K., Wadehra, M. (2008). Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin. Cancer Res., 14(22); 7367-7377.
40. http://www.ablynx.com/research/pipeline.htm.
41. http://en.wikipedia.org/wiki/Single_domain_antibody.
42. http://www.news-medical.net/news/20100804/MabCure-files-provisional-pate nt-application-forovarian- cancer-diagnostic-antibodies.aspx.
43. http://www.businesswire.com/news/home/20101108006638/en/MabCure-Generate s-Tumor- Specific-Antibodies-Prostate-Cancer.
44. Stocks, M. (2005). Intrabodies as drug discovery tools and therapeutics. Curr. Opin. Chem. Biol., 9(4); 359-365.
45. Gal-Tanamy, M., Zemel, R., Bachmatov, L., Jangra, R. K., Shapira, A., Villanueva, R. A., Yi, M., Lemon, S. M., Benhar, I., Tur-Kaspa, R. (2010). Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies. Antiviral Res., 88(1); 95-106. Epub Aug. 10, 2010.
46. http://www.morphosys.com/technologies/morphosys-technologies/hucal-conce pt.
47. Baeuerle, P. A., Reinhardt, C. (2009). Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res., 69(12); 4941-4944. Epub June 9, 2009.
48. http://www.scientificamerican.com/blog/post.cfm?id=plastic-fantastic-syn thetic-antibod-2010-06-09.
49. http://www.medicalnewstoday.com/articles/189404.php.
50. Reichert, J. M. (2008). Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol., 9(6); 423-430.